Released : June 19, 2019 07:00 RNS Number : 7254C MaxCyte, Inc. 19 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") 2018 Annual Report Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that
Gaithersburg, Maryland – May 29, 2019: MaxCyte announced today that Doug Doerfler, Chief Executive Officer, will provide a company overview at the 2019 BIO International Convention on Wednesday, June 5, at 1:15 p.m. ET at the Pennsylvania Convention Center in Philadelphia. In his presentation, Mr.
Released : April 24, 2019 07:00 RNS Number : 8683W MaxCyte, Inc. 24 April 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2018 ¾ First CARMA™ cell therapeutic programme targeting treatment of solid tumours has advanced into
Released : March 19, 2019 17:05 RNS Number : 3554T MaxCyte, Inc. 19 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Issue of Equity Gaithersburg, Maryland - 19 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : February 26, 2019 17:32 RNS Number : 1971R MaxCyte, Inc. 26 February 2019 THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR
Released : February 05, 2019 16:32 RNS Number : 1641P MaxCyte, Inc. 05 February 2019 THIS ANNOUNCEMENT IS RESTRUCTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH
Released : February 05, 2019 07:00 RNS Number : 0847P MaxCyte, Inc. 05 February 2019 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION
Released : March 05, 2019 07:00 RNS Number : 8081R MaxCyte, Inc. 05 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 05 March 2019 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company , announces that on 04
Released : January 15, 2019 07:00 RNS Number : 0746N MaxCyte, Inc. 15 January 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Strong CARMA ™ and financial progress: 19% revenue growth and EBITDA ahead of expectations Gaithersburg, Maryland - 15 JANUARY 2019: MaxCyte
Released : December 17, 2018 18:06 RNS Number : 7483K MaxCyte, Inc. 17 December 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Issue of equity Maryland, USA , 17 December 2018 - MaxCyte (LSE: MXCT) the global cell-based medicines and technology company, announces the
